Historical Valuation
Galmed Pharmaceuticals Ltd (GLMD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.19. The fair price of Galmed Pharmaceuticals Ltd (GLMD) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.85
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Galmed Pharmaceuticals Ltd (GLMD) has a current Price-to-Book (P/B) ratio of 0.24. Compared to its 3-year average P/B ratio of 0.31 , the current P/B ratio is approximately -24.32% higher. Relative to its 5-year average P/B ratio of 0.69, the current P/B ratio is about -66.01% higher. Galmed Pharmaceuticals Ltd (GLMD) has a Forward Free Cash Flow (FCF) yield of approximately -139.24%. Compared to its 3-year average FCF yield of -273.36%, the current FCF yield is approximately -49.06% lower. Relative to its 5-year average FCF yield of -207.49% , the current FCF yield is about -32.89% lower.
P/B
Median3y
0.31
Median5y
0.69
FCF Yield
Median3y
-273.36
Median5y
-207.49
Competitors Valuation Multiple
AI Analysis for GLMD
The average P/S ratio for GLMD competitors is 10.66, providing a benchmark for relative valuation. Galmed Pharmaceuticals Ltd Corp (GLMD.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for GLMD
1Y
3Y
5Y
Market capitalization of GLMD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GLMD in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GLMD currently overvalued or undervalued?
Galmed Pharmaceuticals Ltd (GLMD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.19. The fair price of Galmed Pharmaceuticals Ltd (GLMD) is between to according to relative valuation methord.
What is Galmed Pharmaceuticals Ltd (GLMD) fair value?
GLMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Galmed Pharmaceuticals Ltd (GLMD) is between to according to relative valuation methord.
How does GLMD's valuation metrics compare to the industry average?
The average P/S ratio for GLMD's competitors is 10.66, providing a benchmark for relative valuation. Galmed Pharmaceuticals Ltd Corp (GLMD) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Galmed Pharmaceuticals Ltd (GLMD) as of Jan 09 2026?
As of Jan 09 2026, Galmed Pharmaceuticals Ltd (GLMD) has a P/B ratio of 0.24. This indicates that the market values GLMD at 0.24 times its book value.
What is the current FCF Yield for Galmed Pharmaceuticals Ltd (GLMD) as of Jan 09 2026?
As of Jan 09 2026, Galmed Pharmaceuticals Ltd (GLMD) has a FCF Yield of -139.24%. This means that for every dollar of Galmed Pharmaceuticals Ltd’s market capitalization, the company generates -139.24 cents in free cash flow.
What is the current Forward P/E ratio for Galmed Pharmaceuticals Ltd (GLMD) as of Jan 09 2026?
As of Jan 09 2026, Galmed Pharmaceuticals Ltd (GLMD) has a Forward P/E ratio of -0.68. This means the market is willing to pay $-0.68 for every dollar of Galmed Pharmaceuticals Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Galmed Pharmaceuticals Ltd (GLMD) as of Jan 09 2026?
As of Jan 09 2026, Galmed Pharmaceuticals Ltd (GLMD) has a Forward P/S ratio of 0.00. This means the market is valuing GLMD at $0.00 for every dollar of expected revenue over the next 12 months.